Literature DB >> 11313829

Muscle-specific enhancement of gene expression by incorporation of SV40 enhancer in the expression plasmid.

S Li1, F C MacLaughlin, J G Fewell, M Gondo, J Wang, F Nicol, D A Dean, L C Smith.   

Abstract

Skeletal muscle is established as an ideal tissue for gene delivery to treat systemic diseases. However, the relatively low levels of gene expression obtained from using naturally occurring promoters, including the strong cytomegalovirus (CMV) enhancer/promoter (E/P), have limited the use of muscle as a target tissue. The relatively weak simian virus 40 (SV40) enhancer is known to have dual functions promoting localization of DNA to the nucleus and activating transcription. An SV40 enhancer incorporated either at the 5' end of CMV E/P or the 3' end of the polyadenylation site gave as much as a 20-fold increase in the level of exogenous gene expression in muscle in vivo, compared with expression observed with CMV E/P alone. The minimum requirement for this enhancement is a single copy of a 72-bp element of the SV40 enhancer, in combination with either the CMV E/P or skeletal actin (SkA) promoter. Enhancement of gene expression in muscle by this SV40 enhancer was also observed by using the powerful electroporation delivery. However, the SV40 enhancer does not increase the level of CMV E/P driven reporter gene expression in dividing tumor cells in vivo and in the dividing myoblast cell C2C12 in vitro. The data suggest that including this enhancer in the plasmid will enhance the level of gene production for muscle-based gene therapy.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11313829     DOI: 10.1038/sj.gt.3301419

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  29 in total

Review 1.  Nonviral gene transfer strategies for the vasculature.

Authors:  Jennifer L Young; David A Dean
Journal:  Microcirculation       Date:  2002-01       Impact factor: 2.628

2.  Effect of a DNA nuclear targeting sequence on gene transfer and expression of plasmids in the intact vasculature.

Authors:  J L Young; J N Benoit; D A Dean
Journal:  Gene Ther       Date:  2003-08       Impact factor: 5.250

3.  Electroporation as a method for high-level nonviral gene transfer to the lung.

Authors:  D A Dean; D Machado-Aranda; K Blair-Parks; A V Yeldandi; J L Young
Journal:  Gene Ther       Date:  2003-09       Impact factor: 5.250

Review 4.  Improvement of DNA transfection with cationic liposomes.

Authors:  A Rocha; S Ruiz; J M Coll
Journal:  J Physiol Biochem       Date:  2002-03       Impact factor: 4.158

Review 5.  Applying horizontal gene transfer phenomena to enhance non-viral gene therapy.

Authors:  Jacob J Elmer; Matthew D Christensen; Kaushal Rege
Journal:  J Control Release       Date:  2013-08-30       Impact factor: 9.776

6.  Lung NF-kappaB activation and neutrophil recruitment require IL-1 and TNF receptor signaling during pneumococcal pneumonia.

Authors:  Matthew R Jones; Benjamin T Simms; Michal M Lupa; Mariya S Kogan; Joseph P Mizgerd
Journal:  J Immunol       Date:  2005-12-01       Impact factor: 5.422

Review 7.  Intracellular trafficking of nucleic acids.

Authors:  Rui Zhou; R Christopher Geiger; David A Dean
Journal:  Expert Opin Drug Deliv       Date:  2004-11       Impact factor: 6.648

Review 8.  Nuclear entry of nonviral vectors.

Authors:  D A Dean; D D Strong; W E Zimmer
Journal:  Gene Ther       Date:  2005-06       Impact factor: 5.250

Review 9.  Nonviral gene transfer to skeletal, smooth, and cardiac muscle in living animals.

Authors:  David A Dean
Journal:  Am J Physiol Cell Physiol       Date:  2005-08       Impact factor: 4.249

Review 10.  Plasmid DNA vaccine vector design: impact on efficacy, safety and upstream production.

Authors:  James A Williams; Aaron E Carnes; Clague P Hodgson
Journal:  Biotechnol Adv       Date:  2009-02-20       Impact factor: 14.227

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.